Abiopharma

🔍 Kumar Neil (Executive)

Company: BridgeBio Pharma, Inc. (BBIO)

Report Date: 2025-08-20

Detailed Transactions and Holdings:

• Sold 25,728 shares of Common Stock at $48.8125 per share (Direct)
  Date: 2025-08-20 | Code: S | equity_swap_involved: false | shares_owned_after: 223,518.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 428 shares of Common Stock at $49.2504 per share (Direct)
  Date: 2025-08-20 | Code: S | equity_swap_involved: false | shares_owned_after: 223,090.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-20 | Code: H | nature_of_ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | shares_owned_after: 4,718,447.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-20 | Code: H | nature_of_ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | shares_owned_after: 915,686.00 | Footnotes: F3

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
• F2: Represents the weighted average sale price of the shares sold from $48.22 to $49.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
• F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
• F4: Represents the weighted average sale price of the shares sold from $49.22 to $49.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.